Mavacamten, a cutting-edge cardiac myosin inhibitor, has emerged as a vital treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM)—a condition marked by abnormal thickening of the heart muscle, leading to potential cardiac complications. By reducing excessive cardiac contractility, Mavacamten enhances cardiac function and improves patient outcomes. Recently, the Subject Expert Committee (SEC) within the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) approved the protocol amendment submitted by Bristol-Myers Squibb India Pvt. Ltd. for the ongoing Phase IV clinical study of Mavacamten capsules. The Phase IV study in India, titled ‘ROVER,’ aims to evaluate the safety, tolerability, and efficacy of Mavacamten in adult patients with symptomatic obstructive HCM. This milestone amendment ensures the advancement of research and treatment options for this challenging cardiac disorder.
Read more from medicaldialogues.in